Search details
1.
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
J Hepatol
; 2024 Jun 07.
Article
in English
| MEDLINE | ID: mdl-38857788
2.
Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial.
Hepatology
; 77(6): 2093-2103, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-36800850
3.
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
J Hepatol
; 79(5): 1139-1149, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37524230
4.
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
J Hepatol
; 78(3): 513-523, 2023 03.
Article
in English
| MEDLINE | ID: mdl-38133554
5.
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
J Viral Hepat
; 30(3): 209-222, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36302125
6.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35939812
7.
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
J Hepatol
; 77(5): 1265-1275, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35697332
8.
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
J Hepatol
; 77(3): 642-652, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35460726
9.
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
Hepatology
; 74(4): 1737-1749, 2021 10.
Article
in English
| MEDLINE | ID: mdl-33704806
10.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Hepatology
; 72(1): 58-71, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32115759
11.
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.
J Infect Dis
; 221(3): 389-399, 2020 01 14.
Article
in English
| MEDLINE | ID: mdl-31550363
12.
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Gastroenterology
; 156(5): 1392-1403.e7, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30625297
13.
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
J Hepatol
; 70(5): 1008-1015, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30982526
14.
Sofosbuvir/velpatasvir for 12â¯weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
J Hepatol
; 71(4): 660-665, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31195062
15.
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
J Viral Hepat
; 26(6): 770-773, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30663168
16.
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
Hepatology
; 68(6): 2145-2157, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30070722
17.
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
J Hepatol
; 68(3): 431-440, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29104121
18.
96â¯weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
J Hepatol
; 68(4): 672-681, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29756595
19.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
N Engl J Med
; 373(27): 2608-17, 2015 Dec 31.
Article
in English
| MEDLINE | ID: mdl-26575258
20.
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
Gastroenterology
; 152(6): 1366-1371, 2017 05.
Article
in English
| MEDLINE | ID: mdl-28137593